Articles from Exponential Biotherapies, Inc.
EBI Reaches Key Milestone with First Patient Enrolled in Phase III EasyBoost Trial of EA-230, a Potential First-in-Class Medicine to Accelerate Recovery After Cardiac Surgery
The EasyBoost trial evaluates EA-230 as a potential new treatment option to improve recovery following major cardiac surgery, building on Phase II results in which patients treated with EA-230 had a two-day shorter median hospital stay (8 versus 10 days; p=0.001)
By Exponential Biotherapies, Inc. · Via GlobeNewswire · November 19, 2026
